COMPASS Pathways (NASDAQ:CMPS) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a research note issued to investors on Tuesday morning, Benzinga reports.

A number of other brokerages also recently commented on CMPS. HC Wainwright restated a buy rating and set a $120.00 price objective on shares of COMPASS Pathways in a research report on Friday, March 1st. Morgan Stanley began coverage on shares of COMPASS Pathways in a report on Monday, April 1st. They set an overweight rating and a $30.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of Buy and an average target price of $47.40.

COMPASS Pathways Stock Performance

Shares of CMPS stock opened at $8.53 on Tuesday. The stock’s 50-day moving average price is $9.54 and its 200 day moving average price is $8.46. The company has a quick ratio of 13.33, a current ratio of 13.33 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $528.35 million, a PE ratio of -3.57 and a beta of 2.39. COMPASS Pathways has a 52-week low of $5.01 and a 52-week high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last announced its earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.16). As a group, equities research analysts forecast that COMPASS Pathways will post -2.4 EPS for the current year.

Insider Buying and Selling at COMPASS Pathways

In other news, major shareholder George Jay Goldsmith sold 23,881 shares of the stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $8.53, for a total value of $203,704.93. Following the completion of the transaction, the insider now owns 3,986,523 shares in the company, valued at approximately $34,005,041.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Ekaterina Malievskaia sold 19,853 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $10.59, for a total value of $210,243.27. Following the completion of the transaction, the director now directly owns 4,144,994 shares of the company’s stock, valued at approximately $43,895,486.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder George Jay Goldsmith sold 23,881 shares of the business’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $8.53, for a total value of $203,704.93. Following the sale, the insider now owns 3,986,523 shares in the company, valued at $34,005,041.19. The disclosure for this sale can be found here. Over the last quarter, insiders sold 140,601 shares of company stock valued at $1,338,911. 4.25% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. ARK Investment Management LLC boosted its position in shares of COMPASS Pathways by 7.6% in the 4th quarter. ARK Investment Management LLC now owns 2,618,871 shares of the company’s stock worth $22,915,000 after buying an additional 186,040 shares in the last quarter. Vivo Capital LLC acquired a new stake in shares of COMPASS Pathways in the third quarter valued at approximately $11,899,000. RA Capital Management L.P. purchased a new position in shares of COMPASS Pathways during the 3rd quarter worth approximately $9,516,000. Affinity Asset Advisors LLC acquired a new position in shares of COMPASS Pathways during the 4th quarter worth approximately $4,812,000. Finally, Laurion Capital Management LP lifted its stake in COMPASS Pathways by 169.7% in the 3rd quarter. Laurion Capital Management LP now owns 510,907 shares of the company’s stock valued at $3,781,000 after buying an additional 321,500 shares in the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.